These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12552967)

  • 1. Chemotherapy for small cell lung cancer in patients over 80 years old.
    Ueda H; Kuwahara M; Sakada T; Motohiro A
    Anticancer Res; 2002; 22(6B):3629-31. PubMed ID: 12552967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of small cell lung cancer in elderly.
    Satoh H; Ishikawa H; Funayama Y; Yamashita YT; Kamma H; Ohtsuka M; Sekizawa K
    Anticancer Res; 1999; 19(5C):4507-10. PubMed ID: 10650801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
    Tamiya A; Tsuya A; Nakamura Y; Kaira K; Naitou T; Murakami H; Takahashi T; Endo M; Yamamoto N
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1041-4. PubMed ID: 20567104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
    J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer].
    Tada A; Ueoka H; Kiura K; Tabata M; Takemoto M; Yamane H; Hiyama J; Aoe K; Shibayama T; Kamei H; Kawahara S; Harita S; Sato T; Kobayashi M; Eguchi K; Hiraki S; Hiraki Y; Tanimoto M
    Gan To Kagaku Ryoho; 2002 May; 29(5):751-6. PubMed ID: 12040679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer.
    Banerji U; Ashley S; Coward J; Hughes S; Zee Y; Benepal T; Norton A; Eisen T; O'Brien M
    Lung Cancer; 2006 Dec; 54(3):371-7. PubMed ID: 17049670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].
    Tassinari D; Genestreti G; Pasquini E; Fantini M; Poggi B; Tamburini E; Papi M; Ioli G; Oliverio G; Fochessati F; Arcangeli V; Agostini V; Mianulli AM; Imola M; Fattori PP; Ravaioli A
    Recenti Prog Med; 2005 May; 96(5):234-9. PubMed ID: 15977652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
    Schild SE; Stella PJ; Brooks BJ; Mandrekar S; Bonner JA; McGinnis WL; Mailliard JA; Krook JE; Deming RL; Adjei AA; Jatoi A; Jett JR
    Cancer; 2005 Jun; 103(11):2349-54. PubMed ID: 15852407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer.
    Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):86-90. PubMed ID: 16447041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.